Novo Nordisk’s CEO is looking for new opportunities after losing out to Pfizer in a $10 billion takeover bid for Metsera Inc., an obesity drug developer. The Danish company won’t stop dealmaking, focusing on weight-loss markets and their associated diseases like diabetes.
Source: https://www.bloomberg.com/news/articles/2025-11-08/novo-s-ceo-turns-to-next-targets-after-losing-metsera-to-pfizer